|
Year
|
|
2015–2017
|
81 (63.78%)
|
|
2018–2019 (4 published in 2020 were online first in 2019)
|
46 (36.22%)
|
|
Region of corresponding author
|
|
America (North and South)
|
32 (25.20%)
|
|
Asia
|
35 (27.56%)
|
|
European
|
54 (42.52%)
|
|
Oceania
|
6 (4.72%)
|
|
Reporting guideline claimed by review authors
|
|
PRISMA
|
64 (50.39%)
|
|
MOOSE
|
5 (3.94%)
|
|
Cochrane Handbooka
|
3 (2.36%)
|
|
PRISMA and MOOSE
|
1 (0.79%)
|
|
PRISMA-Pa
|
1 (0.79%)
|
|
No
|
53 (41.73%)
|
|
Use of AMSTAR tool
|
|
Yes
|
5 (3.94%)
|
|
No
|
122 (96.06%)
|
|
Language
|
|
English
|
125 (98.43%)
|
|
Other languages
|
2 (1.57%)
|
|
Type of systematic reviews
|
|
Quantitative review (with meta-analysis)
|
96 (75.59%)
|
|
Narrative review (without meta-analysis)
|
31 (24.41%)
|
|
Type of study for meta-analysis
|
|
Randomized controlled trial (RCT)
|
47 (37.01%)
|
|
Non-randomized study of intervention (NRSI)
|
25 (19.69%)
|
|
Both RCT and NRSI
|
46 (36.22%)
|
|
Not reported
|
9 (7.09%)
|
|
Study number (Median, first and third quartiles)
|
14 (8 to 28)
|
|
2–10
|
48 (37.80%)
|
|
11–20
|
36 (28.35%)
|
|
21–30
|
18 (14.17%)
|
|
> 30
|
25 (19.69)
|
|
Funding
|
|
Non-profit
|
28 (22.05%)
|
|
Profit
|
2 (1.57%)
|
|
Not funded
|
58 (45.67%)
|
|
Not reported
|
39 (30.71%)
|
|
Use of GRADE
|
|
Yes
|
13 (10.24%)
|
|
No
|
1144 (89.76%)
|
